Where PhDs and companies meet
Menu
Login

: Development of novel broad-spectrum antivirals targeting Enterovirus capsid through medicinal chemistry and structure-guided design

ABG-136770 Thesis topic
2026-03-16 Public funding alone (i.e. government, region, European, international organization research grant)
Aix Marseile Universite
MARSEILLE CEDEX 05 - Provence-Alpes-Côte d'Azur - France
: Development of novel broad-spectrum antivirals targeting Enterovirus capsid through medicinal chemistry and structure-guided design
  • Chemistry
  • Health, human and veterinary medicine
medicinal chemistry ; virology

Topic description

Subject / Objective

Enteroviruses represent a persistent global public health threat, being responsible for a wide spectrum of diseases ranging from mild infections to severe complications such as neurological disorders, myocarditis, and ocular infections. The recent emergence of more virulent variants, notably EV-A71 and EV-D68, associated with severe neurological manifestations, highlights the urgent need for the development of new therapeutic strategies. To date, no specific antiviral targeting enteroviruses is available in clinical practice.

This PhD project aims to develop new antiviral inhibitors targeting the viral capsid protein VP1, a key component involved in viral attachment and entry into host cells. The conserved hydrophobic pockets of this protein represent a strategic opportunity for the design of broad-spectrum antivirals.

Building on previous work conducted in the laboratory, which led to the synthesis and evaluation of more than 400 compounds, this project seeks to optimize initial “hit” molecules displaying micromolar to submicromolar antiviral activity to identify new “lead” candidates [1–9].

The project will rely on a multidisciplinary strategy integrating computer-aided drug design, innovative medicinal chemistry approaches (including radical photocatalysis) [10], in vitro biological evaluation, and pharmacokinetic optimization (ADMET studies and formulation strategies). The goal is to identify broad-spectrum drug candidates targeting enteroviruses and polioviruses, paving the way for future preclinical development.

 

1. Roche M et al. Synthesis, biological activity, structure-activity relationship of 4,5-dimethoxybenzene derivatives inhibitor of rhinovirus 14. Eur. J. Med. 2014, 76, 445

2. Lacroix C, Roche M et al.  A novel benzonitrile analogue inhibits rhinovirus replication. J Antimicrob Chemother. 2014, 69, 2723.

3. Da Costa L, Roche M et al. VP1 crystal structure-guided exploration, optimization of 4,5-dimethoxybenzene-based inhibitors of rhinovirus 14 Eur. J. Med. Chem. 2016, 115, 453.

4. Da Costa L, Roche M et al. Heterocyclic pharmacochemistry of rhinovirus antiviral agents: A combined computational and experimental study. Eur. J. Med. Chem. 2017, 140, 528.

 5. Da Costa L, Roche M et al. Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus Replication. J. Med. Chem. 2018, 61, 18, 8402.

6. Roux, H, Roche et al. From the “One Molecule – One Target – One Disease” Concept towards looking for Multi-Target Therapeutics for Treating Non-Polio Enterovirus (NPEV) Infections. Pharmaceuticals. 2024, 17, 9, 1218.

7. Roux, H, Roche M et al, New Potent EV-A71 Antivirals Targeting Capsid. Eur. J. Med. Chem. 2024, 276, 116658.

 8. Roux, H, Roche M et al. Design and Synthesis of Novel Thioether Analogs as Promising Antiviral Agents: Evaluation of In Vitro Activity against Enteroviruses of Interest. Eur. J. Med. Chem. 2025, 288, 117395

9. Roux, H, Roche M et al. Non-Polio Enterovirus Inhibitors: Scaffold, Targets, and Potency, What’s New? ACS Infect. Dis. 2025, 11, 1, 21.

10. Zhao, Y, Broggi. J et al Switching from single to simultaneous free radical and anionic polymerization with enamine-based organic electron donors. Angew. Chem. Int. Ed., 2021, 60, 19389.  

 

Starting date

2026-10-01

Funding category

Public funding alone (i.e. government, region, European, international organization research grant)

Funding further details

competitive examination

Presentation of host institution and host laboratory

Aix Marseile Universite

https://icr.univ-amu.fr/Equipes/radical-pharmaco-chemistry

L’Institut de Chimie Radicalaire, ICR (UMR7273), est une Unité Mixte de Recherche ayant l’Université d’Aix-Marseille et le Centre National de la Recherche Scientifique (CNRS) comme tutelles. Créée le 1 janvier 2012, l’ICR est rattaché à CNRS Chimie. D’un point de vue scientifique, la création de l’ICR a résulté d’une forte volonté de regrouper les compétences complémentaires d’équipes de recherche spécialisées en chimie radicalaire et d’y associer les expertises de deux équipes, centrées sur les méthodes de modélisation et sur la caractérisation moléculaire ou macromoléculaire.

L’objectif principal de l’ICR est double :

Explorer, contrôler et utiliser la réactivité des espèces radicalaires dans des processus chimiques ou biologiques.

Créer de nouvelles espèces radicalaires stables pour des applications ciblées.

 

L’Institut de Chimie Radicalaire est structuré en 8 équipes dont les activités de recherche se situent aux interfaces de la chimie radicalaire, de la synthèse organique, des simulations, des matériaux ou encore de la biologie. Sept équipes (CMO, CRAB, CROPS, CT, SACS, SMBSO, SREP) sont localisées sur le campus de Saint-Jérôme, Av. Esc. Normandie Niemen, 13397 Marseille Cedex 20 ; les équipes PCR et SMBSO sont basées dans les locaux de la Faculté de Pharmacie de Marseille, 27 Bd Jean Moulin, 13385 MARSEILLE Cedex 05.

Structuration

L’unité est structurée en huit équipes de recherche et sa gouvernance est organisée en trois niveaux : la direction, le conseil scientifique et le conseil de laboratoire.

Le conseil scientifique est composé de la direction et des 8 responsables d’équipes.

Le conseil de laboratoire est composé des membres suivants :

• Erwan Adriaenssens (doctorant, équipe CRAB)

• David Bergé-Lefranc (professeur amU, équipe SMBSO)
• Nathalie Blanchi-Marzin (technicienne administrative, pôle gestion)
• Julie Broggi (maître de conférences amU, équipe PCR)

• Nicolas Ferré (professeur amU, directeur ICR)

• Stéphane Gastaldi (directeur de recherche CNRS, directeur-adjoint ICR)
• Micael Hardy (maître de conférences amU, équipe SREP)

• Miquel Huix-Rotllant (chargé de recherche CNRS, équipe CT)

• Anne-Doriane Manick (chargée de recherche CNRS, équipe CROPS)
• Margot Manivel (doctorante, équipe CRAB)
• Sylvain Marque (professeur amU, équipe CRAB)

• Giulia Mollica (directrice de recherche CNRS, directrice-adjointe ICR)

• Dominique Mouysset (ingénieure CNRS, équipe CMO)

• Hélène Pizzala (maître de conférences amU, équipe SACS)

• Vincent Rémusat (ingénieur amU, équipe PCR)

PhD title

PhD Drug design, Chimie médicinale

Country where you obtained your PhD

France

Institution awarding doctoral degree

Aix-Marseille Université

Graduate school

École Doctorale des sciences chimiques

Candidate's profile

Candidate’s Profile

We are seeking a highly motivated and talented candidate with a strong interest in antiviral drug discovery and interdisciplinary research at the interface of chemistry and biology.

The ideal candidate should hold (or be close to obtaining) a Master’s degree (MSc) in Medicinal Chemistry, Organic Chemistry, Pharmaceutical Sciences, or a closely related field. A solid background in organic synthesis and medicinal chemistry is essential.

Experience or knowledge in one or more of the following areas will be highly appreciated:

Organic chemirsty

Computer-aided drug design and molecular modelling

Structure-based drug discovery

 

 

The candidate should demonstrate:

Strong analytical and problem-solving skills

Ability to work independently as well as in a multidisciplinary team

Interest in translational drug discovery and antiviral research

Good scientific communication skills in English (both written and oral)

Previous research experience through internships or Master’s thesis in medicinal chemistry, antiviral research, or drug design will be considered a strong asset.

The successful candidate will join a multidisciplinary research environment, collaborating with chemists, virologists, and computational scientists, and will contribute to the development of innovative antiviral strategies targeting enteroviruses.

2026-03-31
Partager via
Apply
Close

Vous avez déjà un compte ?

Nouvel utilisateur ?